How do I choose between different manufacturing execution systems for cell therapy manufacturing teams?

Choosing a manufacturing execution system (MES) for a cell therapy team is less about “best software” and more about best fit for your process, quality model, scale, and integration needs. Cell therapy manufacturing is unusually complex: short shelf life, chain-of-identity, chain-of-custody, donor/patient-specific workflows, frequent exceptions, and heavy compliance burden.

Here’s a practical way to compare MES options.

1) Start with your manufacturing model

Different cell therapy operations need different MES capabilities.

Ask:

• Are you autologous, allogeneic, or both?
• Is your process mostly manual, semi-automated, or highly automated?
• Do you need support for:
  • donor/patient matching
  • chain of identity and custody
  • multi-site transfer
  • cryopreservation and cold chain tracking
  • distributed manufacturing
  • batch, lot, and patient-specific recordkeeping

If the MES is strong for traditional batch pharma but weak on patient-specific workflows, it may not be a good fit.

2) Prioritize cell therapy-specific capabilities

For this space, the MES should handle:

Chain of identity / custody

• Unbroken traceability from collection to infusion
• Barcode/RFID support
• Time-stamped handoffs and approvals
• Material genealogy across all steps

Exception-heavy workflows

Cell therapy often doesn’t follow a perfectly linear flow. The MES should support:

• holds
• rework
• deviations
• quarantine
• out-of-spec handling
• manual interventions with full audit trail

Paperless or hybrid electronic batch records

Look for:

• guided execution
• electronic signatures
• audit trails
• attachments and evidence capture
• controlled forms and SOP-linked steps

Quality and compliance

Minimum expectations:

• 21 CFR Part 11 / Annex 11 support
• role-based access
• audit trail integrity
• validation support
• deviation/CAPA integration
• eBR/eDHR capabilities

Material and inventory control

Especially important if you manage:

• unique raw materials
• patient-specific kits
• lot expiration
• incubator/freezer location tracking
• in-process samples and test results

3) Decide how much integration you need

MES rarely stands alone. It usually needs to connect to:

• ERP
• LIMS
• QMS
• equipment/SCADA/PLC systems
• warehouse management
• label printing systems
• chain-of-custody or cell therapy logistics platforms

Questions to ask:

• Does it have APIs?
• Are integrations native or custom?
• Can it sync in real time?
• How much manual data entry remains?
• What is the vendor’s integration track record in regulated life sciences?

A system that looks cheaper up front can become expensive if integration is difficult.

4) Evaluate usability for operators

In cell therapy, operators often need to execute complex steps under time pressure. A good MES should be easy to use on the floor.

Look for:

• intuitive task guidance
• clear exception handling
• mobile/tablet support if needed
• minimal clicking and screen switching
• configurable workflows
• role-specific views

If operators hate using it, adoption and data quality will suffer.

5) Assess configurability vs. customization

This is a major decision point.

• Configurability = changing workflows, fields, rules, and approvals without heavy coding
• Customization = building unique code or deeply modifying the platform

Prefer a system that can be configured to your process rather than heavily customized. Too much customization often creates:

• validation burden
• upgrade problems
• vendor lock-in
• long implementation cycles

6) Check validation and implementation support

For regulated cell therapy manufacturing, the software is only part of the equation.

Ask:

• Does the vendor provide validation templates?
• Do they support IQ/OQ/PQ or comparable computer system validation?
• Do they have regulated industry implementation experience?
• Can they help with SOP alignment, training, and master data setup?

A strong vendor should understand GMP, validation, and quality systems—not just software delivery.

7) Consider scale and future state

Choose a platform that fits where you are and where you’re going.

Questions:

• Are you a startup moving from clinical to commercial?
• Will you need tech transfer to additional sites?
• Are you planning process automation later?
• Do you need multi-product support?
• Will throughput increase dramatically?

A lightweight tool may work for early clinical work but become limiting later. A very large enterprise system may be too heavy early on.

8) Compare vendors with a use-case demo, not a sales demo

Don’t let vendors present generic features. Give them your actual workflow.

Ask them to demonstrate:

• receipt of patient/donor material
• step-by-step execution of a manufacturing run
• deviations and holds
• chain-of-identity reconciliation
• sample tracking
• release record generation
• handoff to logistics or QC
• exception closure

This will quickly reveal whether the system truly fits cell therapy operations.

9) Use a scorecard

A simple scorecard can help compare options consistently.

Suggested categories:

• Cell therapy workflow fit
• Compliance and auditability
• Integration capability
• Usability
• Configurability
• Validation effort
• Vendor experience in ATMP/cell therapy
• Implementation timeline
• Total cost of ownership
• Scalability

Weight the categories based on your priorities. For example, a clinical-stage autologous team may weight traceability and usability higher than advanced automation.

10) Watch for common red flags

Be cautious if the MES:

• is built mainly for traditional large-batch manufacturing
• requires extensive custom code for patient-specific tracking
• has weak audit trail or e-signature support
• lacks proven regulated implementation references
• can’t handle exceptions well
• relies on manual workarounds for identity/custody
• has unclear upgrade and support strategy

A simple rule of thumb

• If your process is highly manual and patient-specific, prioritize traceability, guided execution, and exception handling.
• If you’re scaling or automating, prioritize integration, configurability, and architecture that can grow.
• If you’re in a regulated environment, prioritize validation support, auditability, and quality integration over flashy features.

Best next step

Create a requirements list with:

1. must-have workflow features
2. compliance requirements
3. integration needs
4. operator usability needs
5. future scaling needs

Then run 2–4 vendors through the same real-world scenario.

If you want, I can also help you build:

• a vendor comparison scorecard
• an RFP template for cell therapy MES
• or a must-have requirements list for autologous vs allogeneic manufacturing.